Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Completed · Phase 4

Conditions studied: Influenza, Influenza-like Illness

In brief

This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).

Key facts

Study ID

NCT02882100

Run by

Insight Therapeutics, LLC

People needed

823

Starts

2016-04-01

Expected to finish

2023-01-25

Last updated by the study team

2023-03-15

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites

You may not qualify if…

• Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16)
• Facilities having fewer than 50 long-stay residents
• Hospital-based facilities
• Facilities with more than 20% of the population under age 65
• Facilities not submitting Minimum Data Set (MDS) data

Where it is running

• Insight Therapeutics, LLC — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.